← Therapeutics
Details checkedClinical trial listing onlyCheckedregistry
Yiyuancong Adjunct Study for Sudden Sensorineural Hearing Loss
Also known as: Standard treatment combined with Yiyuancong, Yiyuancong herbal paste, Yiyuancong for the Treatment of Sudden Sensorineural Hearing Loss, NCT07505667
Institution-led study
Sponsor / Institution
Institution-led study
Program Type
Therapeutic
Modality
Small Molecule
Stage
Interventional/NA
Status
Active
Target Gene
—
Route / Mode
Oral herbal paste adjunct to standard treatment
Confidence
84%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-10
Geography
China
Population
adult, sudden, sensorineural
Trial IDs
1
Mechanism
Institution-led randomized controlled trial evaluating Yiyuancong herbal paste added to standard treatment versus standard treatment alone for sudden sensorineural hearing loss.
Indications
Notes
Collapsed the generated standard-treatment comparator arm into this Yiyuancong study-level record for NCT07505667. Standard treatment is the active comparator and should not appear as a separate HearScape therapeutic program.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...
IDs: NCT07505667
Key Events
Clinical Trials (1)
Data Checks
institution-led-studyregistry-only-evidenceactive-recruitingcomparator-arm-collapsedstudy-level-not-standalone-product
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2